Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Queensland Health
Fuji
McKinsey
US Army
Covington
Citi
Cipla
UBS

Generated: May 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,043,628

« Back to Dashboard

Which drugs does patent 8,043,628 protect, and when does it expire?

Patent 8,043,628 protects OZURDEX and is included in one NDA.

This patent has fifteen patent family members in ten countries.
Summary for Patent: 8,043,628
Title:Methods for reducing edema
Abstract: Methods for reducing or preventing neovascularization or edema in the eye by implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.
Inventor(s): Wong; Vernon G. (Menlo Park, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:11/932,181
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 8,043,628

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan OZURDEX dexamethasone IMPLANT;INTRAVITREAL 022315-001 Jun 17, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF MACULAR EDEMA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,043,628

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,283,178 Methods for treating edema in the eye and intraocular implants for use therefor ➤ Sign Up
7,625,582 Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor ➤ Sign Up
8,828,446 Method for reducing transplant rejection in the eye and intraocular implants for use therefor ➤ Sign Up
6,699,493 Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Chubb
Fish and Richardson
Deloitte
Fuji
Mallinckrodt
Queensland Health
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.